Key Segmentation
By Indication
-
Rheumatoid Arthritis
-
Plaque Psoriasis
-
Psoriatic Arthritis
-
Ankylosing Spondylitis
-
Others
By Administration Route
-
Subcutaneous Injection
-
Intravenous
-
Others
By Patient Demographics
-
Adults
-
Paediatric
-
Adolescents
-
Others
By Distribution Channel
-
Hospital Pharmacies
-
Retail Pharmacies
-
Online Pharmacies
-
Others
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
UK
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
Ans: Enbrel market is projected to grow modestly at a CAGR of 5.44% from 2025 to 2035, reaching around USD 31.67 billion, with growth concentrated in emerging markets despite biosimilar erosion.
Ans: Online pharmacies are the fastest‑growing channel, with a CAGR of about 6.41%, especially in emerging markets where digital access improves affordability and availability.
Ans: Rheumatoid arthritis is the dominant indication, representing nearly 46.88% of Enbrel’s market share, though its growth is slowing due to biosimilar competition.
Ans: Asia‑Pacific is the fastest‑growing region, with a CAGR of around 7.43%, fueled by expanding healthcare access, rising diagnosis rates, and increasing patient awareness.
Ans: North America holds the largest share, accounting for 40.22% of the market, driven by high autoimmune disease prevalence and strong healthcare infrastructure.